 |
Photo courtesy of Yonhap News |
[Alpha Biz= Kim Jisun] On 6 November 2025 U.S. President Donald Trump announced that pharmaceutical companies Novo Nordisk and Eli Lilly have agreed to significantly reduce monthly prices for several leading obesity treatments in the United States.
Under the agreement:
Prices for injectables such as Wegovy will drop to around US $350 per month, down from over US $1,000.
For Medicare and Medicaid recipients, out-of-pocket co-payments will fall to about US $50 per month.
The agreement relates to the upcoming direct-to-consumer website “TrumpRx” expected to launch in early 2026, through which eligible Americans can purchase these drugs at the new price level.
The move is aimed at widening access to GLP-1 class drugs (such as Wegovy) that have seen huge demand for weight-loss and metabolic treatment, and reflects mounting pressure on drug-pricing in the U.S. market.
Financial Times
알파경제 Kim Jisun Reporter(stockmk2020@alphabiz.co.kr)
